{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:25:17Z","timestamp":1759883117760,"version":"build-2065373602"},"reference-count":14,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>This case report highlights the use of continuous infusion of meropenem in a 42-year-old septic female patient with periprosthetic infection and end-stage renal disease receiving prolonged intermittent renal replacement therapy (PIRRT). Antibiotic infusion in patients receiving renal replacement therapy has its own peculiarities. There are many studies on the optimal dosing regimen for meropenem in renal dysfunction, but studies on the optimal infusion duration in these patients are limited. The patient was admitted with complaints of wounds, necrosis zones of the right upper limb, restriction of joint movements, and temperature increase up to 38 \u00b0C. The patient was treated with a continuous infusion of meropenem 2 g per day receiving renal replacement therapy three times a week (12 h). Also during hospitalization, the patient underwent hip disarticulation and excision of necrotic tissues. The patient was further transferred to a specialized nephrology department for further treatment. We believe that in this clinical case, the use of continuous infusion of meropenem in the complex therapy of sepsis in a patient with CKD undergoing PIRRT sessions helped to lead to clinical improvement in the patient. Further studies are needed.<\/jats:p>","DOI":"10.3390\/medicina61010063","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T10:32:26Z","timestamp":1735813946000},"page":"63","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Meropenem Continuous Infusion in a Septic Patient with Periprosthetic Infection and End-Stage Renal Disease Undergoing Prolonged Intermittent Renal Replacement Therapy"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6702-657X","authenticated-orcid":false,"given":"Assiya","family":"Kadralinova","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, Astana Medical University, Astana 010000, Kazakhstan"},{"name":"Department of Anesthesiology and Intensive Care, National Scientific Center of Traumatology and Orthopedics Named After Academician N.D. Batpenov, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiya","family":"Konkayeva","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, National Scientific Center of Traumatology and Orthopedics Named After Academician N.D. Batpenov, Astana 010000, Kazakhstan"},{"name":"Department of Infectious Diseases and Clinical Epidemiology, Astana Medical University, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serik","family":"Dzhandayev","sequence":"additional","affiliation":[{"name":"Department of Ear, Nose, Throat Diseases, Astana Medical University, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3778-7877","authenticated-orcid":false,"given":"Aidos","family":"Konkayev","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, Astana Medical University, Astana 010000, Kazakhstan"},{"name":"Department of Anesthesiology and Intensive Care, National Scientific Center of Traumatology and Orthopedics Named After Academician N.D. Batpenov, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"ref_1","unstructured":"Bello, A.K., Okpechi, I.G., Levin, A., Ye, F., Saad, S., Zaidi, D., Houston, G., Damster, S., Arruebo, S., and Abu-Alfa, A. (2023). ISN\u2013Global Kidney Health Atlas: A report by the International Society of Nephrology: An Assessment of Global Kidney Health Care Status focussing on Capacity, Availability, Accessibility, Affordability and Outcomes of Kidney Disease. Int. Soc. Nephrol., 3."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1080\/07853890.2021.1987511","article-title":"Sepsis in end-stage renal disease patients: Are they at an increased risk of mortality?","volume":"53","author":"Tamim","year":"2021","journal-title":"Ann. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.kint.2016.07.013","article-title":"Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality","volume":"90","author":"Tang","year":"2016","journal-title":"Kidney Int."},{"key":"ref_4","first-page":"475","article-title":"Nephrotoxic and peroxidative potential of meropenem and imipenem\/cilastatin in rat and human renal cortical slices and microsomes","volume":"37","author":"Yousif","year":"1999","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/jcph.727","article-title":"Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy","volume":"56","author":"Lewis","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/FTD.0000000000000741","article-title":"Population Pharmacokinetic Analysis of Meropenem in Critically Ill Patients with Acute Kidney Injury Treated with Continuous Hemodiafiltration","volume":"42","author":"Niibe","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jcrc.2020.09.001","article-title":"Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy","volume":"60","author":"Chaijamorn","year":"2020","journal-title":"J. Crit. Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1186\/s13018-020-02117-3","article-title":"Comparison of total joint arthroplasty outcomes between renal transplant patients and dialysis patients meta-analysis and systematic review","volume":"15","author":"Li","year":"2020","journal-title":"J. Orthop. Surg. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/jcph.1595","article-title":"Evaluation of Hemodialysis Effect on Pharmacokinetics of Meropenem\/Vaborbactam in End-Stage Renal Disease Patients Using Modeling and Simulation","volume":"60","author":"Zhuang","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00063-018-0455-5","article-title":"Pharmacotherapy and kidney dysfunction","volume":"114","author":"Keller","year":"2019","journal-title":"Med. Klin-Intensivmed. Notfallmedizin"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13318-021-00709-w","article-title":"Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation","volume":"46","author":"Larcher","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1097\/CCM.0b013e3181aab3d0","article-title":"Principles of antibacterial dosing in continuous renal replacement therapy","volume":"37","author":"Choi","year":"2009","journal-title":"Crit. Care Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/cc10257","article-title":"Recommended lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy","volume":"15","author":"Seyler","year":"2011","journal-title":"Crit. Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijantimicag.2014.09.009","article-title":"Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomized controlled trial of continuous infusion versus intermittent bolus administration","volume":"45","author":"Jamal","year":"2015","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/1\/63\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:23:48Z","timestamp":1759850628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/1\/63"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["medicina61010063"],"URL":"https:\/\/doi.org\/10.3390\/medicina61010063","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2025,1,2]]}}}